TotalMarketCap

Intellia Therapeutics

NTLANasdaq United StatesHealth CareBiotechnology: In Vitro & In Vivo Diagnostic Substances

Market cap

$1.560 B

$11.14 -9.54%

Close of 6 Nov 2026

As of 6 Nov 2026, Intellia Therapeutics (NTLA) has a market capitalization of $1.56B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$67.7M

#2615 by revenue

Earnings

-$412.7M

Loss-making

Shares outstanding

140,358,512

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: In Vitro & In Vivo Diagnostic Substances, ranked by market cap

All 19 →
  1. #4NeogenNEOG$2.54B
  2. #5Celldex TherapeuticsCLDX$2.22B
  3. #6Intellia TherapeuticsNTLA$1.56B
  4. #7QuidelOrthoQDEL$886.3M
  5. #8Achieve Life SciencesACHV$658.1M

What if Intellia Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$201,509.60

Per share 18,097× higher

Bitcoin $1.53T

$10,903.33

Per share 979× higher

Apple $5.02T

$35,794.63

Per share 3,215× higher

Or at a round number

$2.00B$5.00B$10.0B$20.0B

Where these numbers come from

Share counts and financials for Intellia Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.